Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $180 from $165 and keeps a Buy rating on the shares and its “Best Idea” designation after the company reported “hefty” EBITDA upside in Q1. Q1 was a “great start to 2025,” and “certainly a welcome reprieve” amid a backdrop where potential headwinds are top of mind, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $171 from $161 at Barclays
- Tenet Healthcare’s Strategic Expansion and Strong Financial Performance Highlighted by Conservative Guidance and Robust Margins
- Tenet Healthcare Reports Strong Q1 2025 Results
- Tenet Healthcare’s Strong Q1 Performance Amid Policy Uncertainty
- Tenet Healthcare’s Strong Performance and Strategic Focus Justify Buy Rating